title: Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations.
abstract: Advanced basal cell carcinomas are a subset of basal cell carcinomas that can be difficult to treat either due to their local invasiveness, proximity to vital structures, or metastasis. The incidence of all basal cell carcinoma is increasing in the United States, although it is not known whether advanced basal cell carcinomas (aBCCs) are also increasing. Recently, highly targeted therapy based on knowledge of the basal cell carcinoma pathogenesis has become available either commercially or through human clinical trials. These orally available drugs inhibit the Hedgehog signaling pathway, and lead to advanced basal cell carcinoma shrinkage that can enable preservation of adjacent vital organs. In this review, we outline the role of Hedgehog pathway inhibitors as well as other treatment modalities such as excision, radiotherapy and more traditional chemotherapy in treating advanced basal cell carcinomas. We also highlight current gaps in knowledge regarding the use and side effects of this targeted therapy.
authors.affiliation: Department of Dermatology, Stanford University School of Medicine, 450 Broadway St, MC 5334, Pavilion C, 2nd floor, Redwood City, CA 94063 USA.
authors.forename: Shalini V
authors.initials: SV
authors.lastname: Mohan
authors.affiliation: Department of Dermatology, Stanford University School of Medicine, 450 Broadway St, MC 5334, Pavilion C, 2nd floor, Redwood City, CA 94063 USA.
authors.forename: Anne Lynn S
authors.initials: AL
authors.lastname: Chang
keywords: Advanced basal cell carcinoma; Basal cell carcinoma; Basal cell nevus syndrome; Gorlin’s syndrome; Hedgehog pathway inhibitors; Metastatic basal cell carcinoma; Smoothened inhibitors; Targeted therapy; Vismodegib